Clinical Study of Modified Banxia Xiexin Decoction Treatment on Gastric Cancer
Gastric Cancer (Diagnosis)
About this trial
This is an interventional treatment trial for Gastric Cancer (Diagnosis) focused on measuring Modified Banxia Xiexin Decoction, Gastric Cancer, Clinical Efficacy, Randomized clinical trial, Mechanism
Eligibility Criteria
Inclusion Criteria: Patients with stage IV gastric cancer with a clear cytological or pathological diagnosis. The patient is willing to receive palliative chemotherapy (more than 6 months between the first treatment or the last chemotherapy). At least one measurable lesion revealed by imaging (PET-CT, CT, MRI, bone scan, x-ray). Expected survival of ≥ 6 months. It is consistent with the diagnosis of spleen qi deficiency and cold-heat mismatch in TCM. Age 18 to 75 years with a physical condition score of ECOG (0-1). The blood count is normal, heart, liver and kidney functions are not abnormal, and the electrocardiogram is basically normal. Patients have good compliance, are able to understand the study and sign an informed consent form. Exclusion Criteria: Those with a history of severe cardiovascular, urinary, hematological and digestive system diseases. Pregnant or breastfeeding women with uncontrollable mental disorders. With gastrointestinal obstruction or active bleeding in the gastrointestinal tract, as well as perforation and dysphagia. Complications of serious infectious diseases such as active tuberculosis. Those with contraindications to chemotherapy or frequent vomiting. Poor compliance. Patients who have used other trial drugs or in other clinical trials in the past month.
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Active Comparator
Placebo Comparator
combination chemotherapy with Modified Banxia Xiexin Decoction
combination chemotherapy with Placebo granules
146 patients with gastric cancer were randomly divided into a treatment group of 73 cases and a control group of 73 cases. The treatment group received combination chemotherapy with Modified Banxia Xiexin Decoction
The control group received combination chemotherapy with Placebo granules.